



ASX Announcement

17 August 2018

Entitlement Issue: Shortfall Notice

Creso Pharma Limited (ASX: CPH, the “Company” or “Creso”) advises that the Non-Renounceable Entitlement Issue announced to the ASX on 23 July 2018 (“**Entitlement Issue**”), closed on the 14 August 2018.

The Entitlement Issue offered eligible shareholders registered on the Record Date the ability to subscribe for Options on the basis of one (1) Option for every two (2) Shares held at an issue price of \$0.05 per Option to raise up to \$2.8 million before costs (“**Entitlement Issue Options**”).

Applications were received under the Entitlement Issue for a total of 24,377,710 Options raising gross proceeds of \$1,218,885.50. Of the gross proceeds, \$518,648 was contributed by the Directors of the Company by way of participation in the Entitlement Issue. The Options will be issued as per the timetable for the Entitlement Issue.

The results of the Entitlement Issue as follows;

- Number of Entitlement Issue Options taken up: 24,377,710
- Shortfall: 33,485,865
- **Total Number of Options: 57,863,575**

As per the Prospectus, the Board reserves the right to place the remaining Shortfall Options within three months after the closing date of the offer being 14 November 2018.

-ENDS-

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 0000